PharmaCom BioVet to File With FDA in Order to Perform Clinical Trials

  PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is
pleased to announce that it is preparing a Form 21 CFR 511.1(b) for
submission to the Federal Drug Administration (FDA).  This initial form is
one of several required if the Corporation decides to potentially run
clinical trials on a histone deacetylase inhibitor for canines, which the
Corporation is planning to develop.  The histone deacetylase inhibitor is
potentially for dogs suffering from an acute type of cancer, canine
hemangiosarcoma.

"We are pleased to announce this filing with the FDA, because it is another positive step towards implementing our business plan and could possibly lead to future testing of cancer treatment medications for canines," stated Gary Berthold, President of PharmaCom BioVet, Inc.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a potentially greater life expectancy and decreased suffering. To learn more, please go to the Corporations Web site www.pharmacombiovet.com

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control

Contact: Investor Relations Tel: [phone] URL: http://www.PharmaComBioVet.com